% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Frisoni:281510,
      author       = {Frisoni, Giovanni B and Hansson, Oskar and Nichols, Emma
                      and Garibotto, Valentina and Schindler, Suzanne E and van
                      der Flier, Wiesje M and Jessen, Frank and Villain, Nicolas
                      and Arenaza-Urquijo, Eider M and Crivelli, Lucia and Fortea,
                      Juan and Grinberg, Lea T and Ismail, Zahinoor and Minoshima,
                      Satoshi and Ossenkoppele, Rik and Zetterberg, Henrik and
                      Petersen, Ronald C and Dubois, Bruno},
      title        = {{N}ew landscape of the diagnosis of {A}lzheimer's disease.},
      journal      = {The lancet},
      volume       = {406},
      number       = {10510},
      issn         = {0140-6736},
      address      = {London [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DZNE-2025-01131},
      pages        = {1389 - 1407},
      year         = {2025},
      abstract     = {Alzheimer's disease involves a drastic departure from the
                      cognitive, functional, and behavioural trajectory of normal
                      ageing, and is both a dreaded and highly prevalent cause of
                      disability to individuals, and a leading source of health
                      and social care expenditure for society. Before the advent
                      of biomarkers, post-mortem examination was the only method
                      available to establish a definitive diagnosis. In this first
                      paper of the Series, we review state-of-the-art diagnostic
                      practices and the typical patient journey in specialist
                      settings, where clinicians engage in a differential
                      diagnosis to establish whether Alzheimer's pathology
                      (cerebral deposition of β-amyloid and hyperphosphorylated
                      tau) is a contributor to cognitive impairment. Biomarkers
                      indicating dysregulation of β-amyloid and tau homeostasis,
                      measured with PET and cerebrospinal fluid analysis, allow a
                      molecular-level diagnosis-a mandatory step in defining
                      eligibility for the recently approved anti-amyloid
                      treatments. We anticipate that easily accessible blood
                      biomarkers, already available in some countries, will lead
                      to a new diagnostic revolution and bring about major changes
                      in health-care systems worldwide.},
      subtyp        = {Review Article},
      keywords     = {Humans / Alzheimer Disease: diagnosis / Alzheimer Disease:
                      cerebrospinal fluid / Biomarkers: cerebrospinal fluid /
                      Biomarkers: blood / Amyloid beta-Peptides: metabolism /
                      Amyloid beta-Peptides: cerebrospinal fluid / tau Proteins:
                      cerebrospinal fluid / tau Proteins: metabolism / Diagnosis,
                      Differential / Positron-Emission Tomography / Biomarkers
                      (NLM Chemicals) / Amyloid beta-Peptides (NLM Chemicals) /
                      tau Proteins (NLM Chemicals)},
      cin          = {AG Jessen},
      ddc          = {610},
      cid          = {I:(DE-2719)1011102},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40997838},
      doi          = {10.1016/S0140-6736(25)01294-2},
      url          = {https://pub.dzne.de/record/281510},
}